BA
SYRS

BlackRock Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

BlackRock Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$23K Buy
+189
New +$26.5K ﹤0.01% 3430

Other funds holding SYRS

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock Advisors's SYRS Position: Q4 2016 in Review

BlackRock Advisors opened a new position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2016: 189 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #3430 among its holdings.

42 funds tracked by Wall St. Rank hold SYRS as of Q4 2016.

  • BlackRock Advisors held 189 shares of Syros Pharmaceuticals, Inc. Common Stock worth $23K as of Q4 2016.
  • Syros Pharmaceuticals, Inc. Common Stock was a new BlackRock Advisors position in Q4 2016.
  • Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3430 holding.
  • 42 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.